ドパミン取り込み阻害薬、ドーパミン取り込み阻害薬、ドパミン取り込み阻害剤、ドーパミン取り込み阻害剤、ドパミン取り込み抑制薬、ドーパミン取り込み抑制薬

関: dopamine reuptake inhibitor

WordNet

limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
limit the range or extent of; "Contact between the young was inhibited by strict social customs"
a process of taking up or using up or consuming; "they developed paper napkins with a greater uptake of liquids"
a substance that retards or stops an activity
a monoamine neurotransmitter found in the brain and essential for the normal functioning of the central nervous system; as a drug (trade names Dopastat and Intropin) it is used to treat shock and hypotension (同)Dopastat, Intropin

PrepTutorEJDIC

〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
〈U〉《the up. take》《話》理解,予解 / 〈C〉(鉱山などで空気や煙の)吸い上げパイプ
抑制する人(物) / 化学反応抑制剤

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/07 06:32:28」(JST)

wiki en

[Wiki en表示]

A dopamine reuptake inhibitor (DRI) is a type of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron. This, in turn, leads to increased extracellular concentrations of dopamine and therefore an increase in dopaminergic neurotransmission.^[1]

DRIs are frequently used in the treatment of conditions like ADHD and narcolepsy on account of their psychostimulant effects and in the treatment of obesity due to their appetite suppressant properties. They have also been used as antidepressants in the treatment of mood disorders, but their use for this indication has been limited on account of their abuse potential and legal restrictions. Lack of dopamine reuptake and the increase in extracellular levels of dopamine have been linked to increased susceptibility to addictive behavior due to the increase in dopaminergic neurotransmission.^{[citation needed]} The dopaminergic pathways are considered to be strong reward centers. In addition, many DRIs such as cocaine are drugs of abuse due to the rewarding effects evoked by elevated synaptic concentrations of dopamine in the brain.

Society and culture

History of use

Until the 1950s, dopamine was thought to be nothing but part of the biosynthesis of norepinephrine and epinephrine. It was not until dopamine was found in the brain in same levels as norepinephrine that it was considered that dopamine might have a biological role other than the synthesis of the catecholamines.^[2]

Pharmacotherapeutic uses

The following drugs have DRI action and have been or are used clinically specifically for this property: amineptine, bromantane, dexmethylphenidate, difemetorex, fencamfamine, lefetamine, levophacetoperane, medifoxamine, mesocarb, methylphenidate, nomifensine, pipradrol, prolintane, and pyrovalerone. The following drugs are or have been used clinically and possess only weak DRI action, which may or may not be clinically-relevant: adrafinil, armodafinil, bupropion, mazindol, modafinil, nefazodone, sertraline, and sibutramine. The following drugs are or have been clinically used but only coincidentally have DRI properties: benzatropine, diphenylpyraline, etybenzatropine, ketamine, nefopam, pethidine (meperidine), and tripelennamine. And, while virtually all DRIs are abused recreationally, the following are a selection of some particularly notable ones: cocaine, ketamine, MDPV, naphyrone, and phencyclidine (PCP). Amphetamines, including amphetamine, methamphetamine, MDMA, cathinone, methcathinone, mephedrone, and methylone, are all DRIs as well, but are distinct in that they additionally behave, and often much more potently, as dopamine releasing agents (DRAs).

Recently, the FDA-approved wakefulness-promoting agent modafinil and its analogues (e.g., adrafinil, armodafinil, fluorenol), which are approved to treat narcolepsy and shift work sleep disorder,^[3] were found to act as weak (micromolar) DRIs.^[4] However, this property has been found to not correlate with their wakefulness-promoting effects, suggesting that it is too weak to be of clinical significance and that these drugs promote wakefulness via some other mechanism.^[5]

DRIs have been explored as potential antiaddictive agents because of their ability to replace reward received from other drugs. DRIs have been successfully used to serve as nicotine replacements in cases of smoking addictions well as methadone replacements in the case of heroin addiction. DRIs have been explored as potential substitutes for cocaine addiction, and have been shown to alleviate cravings and self-administration.^[6]

Monoamine reuptake inhibitors, including DRIs, have also been shown to be effective as therapy for food intake and appetite control for obese subjects. However, most marketed drugs for this purpose have been withdrawn or discontinued due to adverse side effects such as increase in blood pressure and high abuse potential.^[7]

List of DRIs

3D structure of RTI-470, a high-affinity and selective DAT ligand^[8]

Many DRIs exist, an assortment which are listed below. Note that only DRIs which are selective for the DAT over the other monoamine transporters (MATs) are listed below. For a list of DRIs that act at multiple MATs, see other monoamine reuptake inhibitor pages such as NDRI and SNDRI.

Selective dopamine reuptake inhibitors

Altropane (O-587)
Amfonelic acid (WIN 25978)
Amineptine (has a reasonable degree of selectivity for dopamine over norepinephrine reuptake inhibition)
BTCP (GK-13)
DBL-583
Difluoropine (O-620)
GBR-12783
[(Cocaine)]
GBR-12935
GBR-13069
GBR-13098
GYKI-52895
Iometopane (β-CIT, RTI-55)
JHW-007
RTI-229
Vanoxerine (GBR-12909)

DRIs with activity at other sites

Adrafinil (weak)
Armodafinil (weak)
Fluorenol (extremely weak)
Medifoxamine
Metaphit (irreversible; depletes dopamine)
Modafinil (weak)
Rimcazole

Other DRIs

Chaenomeles speciosa (Flowering Quince)^[9]
Oroxylin A (found in Oroxylum indicum and Scutellaria baicalensis (Skullcap))^[10]
Kavain and desmethoxyyangonin (possibly) (found in Piper methysticum (Kava))
[(Coca)]

References

^ Rui Song; Hai-Ying Zhang, Xia Li, Guo-Hua Bi, Eliot L. Gardner, Zheng-Xiong Xi (5 September 2012). "Increased vulnerability to cocaine in mice lacking dopamine D3 receptors". PNAS 109: 17675–17680. doi:10.1073/pnas.1205297109.
^ Jack R. Cooper; Floyd E. Bloom; Robert H. Roth (1996). "9". The Biochemical Basis of Neuropharmacology (7th ed.). Oxford University Press, Inc. p. 293.
^ Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (February 21, 2012). Alessi-Severini, Silvia, ed. "The prevalence and cost of unapproved uses of top-selling orphan drugs". PLoS ONE 7 (2): e31894. doi:10.1371/journal.pone.0031894. PMC 3283698. PMID 22363762.
^ Loland, C.J.; M. Mereu; O.M. Okunola; J. Cao; T.E. Prisinzano; T. Kopajtic; L. Shi; J.L. Katz; G. Tanda; A.H. Newman (1 September 2012). "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.". Biol. Psychiatry 72 (5): 405–13. doi:10.1016/j.biopsych.2012.03.022. PMC 3413742. PMID 22537794.
^ Wise RA (1996). "Neurobiology of addiction". Curr. Opin. Neurobiol. 6 (2): 243–51. doi:10.1016/S0959-4388(96)80079-1. PMID 8725967.
^ Carroll, F. Ivy; James L. Howard; Leonard L. Howell; Barbara S. Fox; Michael J. Kuhar (24 March 2006). "Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse". The AAPS Journal. 1 8. Retrieved 11-12-2012. Check date values in: |accessdate= (help)
^ Kintscher, U (2012). "Reuptake Inhibitors of Dopamine, Noradrenaline, and Seratonin". Handbook of Experimental Pharmocology 209: 339–347. doi:10.1007/978-3-642-24716-3_15.
^ doi:10.1208/aapsj080124 PMID 16584128
^ Zhao G, Jiang ZH, Zheng XW, Zang SY, Guo LH (September 2008). "Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract". Pharmacology, Biochemistry, and Behavior 90 (3): 363–71. doi:10.1016/j.pbb.2008.03.014. PMID 18485464.
^ Yoon, Seo Young; dela Peña, Ike; Kim, Sung Mok; Woo, Tae Sun; Shin, Chan Young; Son, Kun Ho; Park, Haeil; Lee, Yong Soo; Ryu, Jong Hoon; Jin, Mingli; Kim, Kyeong-Man; Cheong, Jae Hoon (2013). "Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro". Archives of Pharmacal Research 36 (1): 134–140. doi:10.1007/s12272-013-0009-6. ISSN 0253-6269.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ドーパミンの腎臓作用 renal actions of dopamine
2. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
3. パーキンソン病に対する神経保護療法 neuroprotective therapy for parkinson disease
4. 排卵誘発の概要 overview of ovulation induction
5. 昇圧剤および強心剤の使用 use of vasopressors and inotropes

English Journal

Renal tubular secretion of pramipexole.

Knop J1, Hoier E1, Ebner T2, Fromm MF3, Müller F1.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2015 Nov 15;79:73-8. doi: 10.1016/j.ejps.2015.09.004. Epub 2015 Sep 7.
The dopamine agonist pramipexole is cleared predominantly by the kidney with a major contribution of active renal secretion. Previously the organic cation transporter 2 (OCT2) was shown to be involved in the uptake of pramipexole by renal tubular cells, while the mechanism underlying efflux into tub
PMID 26360835

Dopamine uptake dynamics are preserved under isoflurane anesthesia.

Brodnik ZD1, España RA2.
Neuroscience letters.Neurosci Lett.2015 Oct 8;606:129-34. doi: 10.1016/j.neulet.2015.08.046. Epub 2015 Aug 28.
Fast scan cyclic voltammetry is commonly used for measuring the kinetics of dopamine release and uptake. For experiments using an anesthetized preparation, urethane is preferentially used because it does not alter dopamine uptake kinetics compared to freely moving animals. Unfortunately, urethane is
PMID 26321152

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.

Levin ED1, Wells C2, Johnson JE2, Rezvani AH2, Bymaster FP3, Rose JE2.
European journal of pharmacology.Eur J Pharmacol.2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20.
A wider diversity of drug treatments to aid smoking cessation is needed to help tailor the most efficacious treatment for different types of smokers. This study was conducted to determine whether amitifadine, which inhibits re-uptake of dopamine, norepinephrine and serotonin, would decrease nicotine
PMID 26101069

Japanese Journal

Antiallodynic Action of 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), a Betaine/GABA Transporter Inhibitor

Journal of Pharmacological Sciences 125(2), 217-226, 2014
NAID 130004438625

Effect of GBR12909 on affective behavior: Distinguishing motivational behavior from antidepressant-like and addiction-like behavior using the runway model of intracranial self-stimulation

Behavioural Brain Research 243, 313-321, 2013-04-15
NAID 120005311980

PJ-195 A Dopamine Re-uptake Inhibitor Terminates Atrial Fibrillation and Flutter in the Canine Sterile Pericarditis Model(Arrhythmia, diagnosis/pathophysiology/EPS-11, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Circulation journal : official journal of the Japanese Circulation Society 71(Supplement_I), 520, 2007-03-01
NAID 110006397870

「ドパミン取り込み阻害薬」

　　[★]

英: dopamine uptake inhibitor
関: ドーパミン取り込み阻害薬、ドパミン再取り込み阻害薬、ドパミン再取り込み阻害剤、ドーパミン取り込み阻害剤、ドパミン取り込み阻害剤、ドパミン取り込み抑制薬、ドーパミン取り込み抑制薬

「ドーパミン取り込み阻害剤」

　　[★]

英: dopamine uptake inhibitor
関: ドパミン取り込み阻害薬、ドーパミン取り込み阻害薬、ドパミン再取り込み阻害薬、ドパミン再取り込み阻害剤、ドパミン取り込み阻害剤、ドパミン取り込み抑制薬、ドーパミン取り込み抑制薬

「ドパミン取り込み抑制薬」

　　[★]

英: dopamine uptake inhibitor
関: ドパミン取り込み阻害薬、ドーパミン取り込み阻害薬、ドーパミン取り込み阻害剤、ドパミン取り込み阻害剤、ドーパミン取り込み抑制薬

「ドパミン取り込み阻害剤」

　　[★]

英: dopamine uptake inhibitor
関: ドパミン取り込み阻害薬、ドーパミン取り込み阻害薬、ドーパミン取り込み阻害剤、ドパミン取り込み抑制薬、ドーパミン取り込み抑制薬

「ドーパミン取り込み抑制薬」

　　[★]

英: dopamine uptake inhibitor
関: ドパミン取り込み阻害薬、ドーパミン取り込み阻害薬、ドーパミン取り込み阻害剤、ドパミン取り込み阻害剤、ドパミン取り込み抑制薬

「inhibit」

　　[★]

v.

抑制する、阻害する、阻止する

関: abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression

「inhibitor」

　　[★]

n.

阻害剤、阻害薬、抑制薬、抑制剤、(内在性物質について)インヒビター、抑制物質

関: blocker、depressant、suppressant

「uptake」

　　[★]

n.

取り込み、取込み

v.

取り込む

関: incorporate、incorporation

[1] Rui Song; Hai-Ying Zhang, Xia Li, Guo-Hua Bi, Eliot L. Gardner, Zheng-Xiong Xi (5 September 2012). "Increased vulnerability to cocaine in mice lacking dopamine D3 receptors". PNAS 109: 17675–17680. doi:10.1073/pnas.1205297109.

[2] Jack R. Cooper; Floyd E. Bloom; Robert H. Roth (1996). "9". The Biochemical Basis of Neuropharmacology (7th ed.). Oxford University Press, Inc. p. 293.

[3] Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (February 21, 2012). Alessi-Severini, Silvia, ed. "The prevalence and cost of unapproved uses of top-selling orphan drugs". PLoS ONE 7 (2): e31894. doi:10.1371/journal.pone.0031894. PMC 3283698. PMID 22363762.

[4] Loland, C.J.; M. Mereu; O.M. Okunola; J. Cao; T.E. Prisinzano; T. Kopajtic; L. Shi; J.L. Katz; G. Tanda; A.H. Newman (1 September 2012). "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.". Biol. Psychiatry 72 (5): 405–13. doi:10.1016/j.biopsych.2012.03.022. PMC 3413742. PMID 22537794.

[pmid8725967-5] Wise RA (1996). "Neurobiology of addiction". Curr. Opin. Neurobiol. 6 (2): 243–51. doi:10.1016/S0959-4388(96)80079-1. PMID 8725967.

[6] Carroll, F. Ivy; James L. Howard; Leonard L. Howell; Barbara S. Fox; Michael J. Kuhar (24 March 2006). "Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse". The AAPS Journal. 1 8. Retrieved 11-12-2012. Check date values in: |accessdate= (help)

[7] Kintscher, U (2012). "Reuptake Inhibitors of Dopamine, Noradrenaline, and Seratonin". Handbook of Experimental Pharmocology 209: 339–347. doi:10.1007/978-3-642-24716-3_15.

[8] :10.1208/aapsj080124 PMID 16584128

[pmid18485464-9] Zhao G, Jiang ZH, Zheng XW, Zang SY, Guo LH (September 2008). "Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract". Pharmacology, Biochemistry, and Behavior 90 (3): 363–71. doi:10.1016/j.pbb.2008.03.014. PMID 18485464.

[Yoondela_Pe.C3.B1a2013-10] Yoon, Seo Young; dela Peña, Ike; Kim, Sung Mok; Woo, Tae Sun; Shin, Chan Young; Son, Kun Ho; Park, Haeil; Lee, Yong Soo; Ryu, Jong Hoon; Jin, Mingli; Kim, Kyeong-Man; Cheong, Jae Hoon (2013). "Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro". Archives of Pharmacal Research 36 (1): 134–140. doi:10.1007/s12272-013-0009-6. ISSN 0253-6269.

リンク元	「ドパミン取り込み阻害薬」「ドーパミン取り込み阻害剤」「ドパミン取り込み抑制薬」「ドパミン取り込み阻害剤」「ドーパミン取り込み抑制薬」
関連記事	「inhibit」「inhibitor」「uptake」

匿名

検索

案内

案内

dopamine uptake inhibitor